KLH in Clinical Trials

Clinical trials involving KLH. Details such as study status, design and investigators are available by link to outside sites.

Clinical trial links are intended for informational purposes only, and are not solicitations for any study nor provided for the purposes of giving medical advice. See Terms of Use for this site.

(in order by date)

Entries in Therapeutic Vaccine (118)

Tuesday
Nov292016

NCT02980198

Wednesday
Oct122016

NCT02947854

Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant

An Open-label, Phase I/Proof of Principle, Dose Escalation Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation (PCI) of Antigen/Adjuvant in Healthy Male/Female Subjects

Condition: Healthy Volunteers
Sponsor: PCI Biotech
Phase 1 


Monday
Apr182016

NCT02745756

A Combined Cell Therapy Approach to the Treatment of Neuroblastoma

A Combined Cell Therapy Approach to the Treatment of Neuroblastoma

Conditions: Neuroblastoma, Nerve Tissue Neoplasms
Sponsor: H. Lee Moffitt Cancer Center & Research Institute
Collaborator: All Childrens Hosp Johns HopkinsMedicine 
Phase 1 

Tuesday
Nov172015

NCT02665364

Study of IFN-K in Systemic Lupus Erythematosus

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus

Condition: Systemic Lupus Erythematosus
Sponsor: Neovacs
Phase 2 

Friday
Oct092015

NCT02579252

24 Months Safety and Efficacy Study of AADvac1 in Patients with Mild Alzheimer's Disease (ADAMANT)

A 24 Months Randomised, Placebo-controlled, Parallel Group, Double Blinded, Multi Centre, Phase 2 Study to Assess Safety and Efficacy of AADvac1 Applied to Patients With Mild Alzheimer's Disease

Condition: Alzheimer's Disease
Sponsor: Axon Neuroscience SE
Phase 2 

Tuesday
Aug252015

NCT02543749

DC Vaccination in CML

Dendritic Cells as Autologous Vaccine in Patients With Chronic Myeloid Leukemia

Condition: Chronic Myeloid Leukemia
Sponsor: Charite University, Berlin, Germany
Phase 1
Phase 2  

Friday
Jul242015

NCT02508896

Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects (AFF012)

A Single-blind Phase 1 Study Assessing the Safety, Immunogenicity and Low Density Lipoprotein Cholesterol (LDLc)-Lowering Activity of 2 Different Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Targeting AFFITOPE® Vaccines in Healthy Subjects

Condition: Hypercholesterolemia
Sponsor: Affiris AG
Collaborator: Medical University of Vienna
Phase 1
 

Friday
May222015

NCT02455557

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma

Condition: Glioblastoma
Sponsor: Roswell Park Cancer Institute
Collaborator: National Cancer Institute (NCI) 
Phase 2 

Tuesday
Jan062015

NCT02334865

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients With Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Conditions: Multiple Myeloma or Plasma Cell Leukemia, Plasma Cell Myeloma
Sponsor: Roswell Park Cancer Institute
Collaborator: National Cancer Institute (NCI) 
Phase 1

Tuesday
Jan062015

NCT02334735

A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence

A Phase II Open Label, Randomized Study of Poly-ICLC Matured DC as an Adjuvant for NY-ESO-1 and Melan-A/MART-1 Peptide Vaccination Compared to Montanide® ISA-51 VG, in Study Subjects With Melanoma in Complete Clinical Remission But at High Risk of Disease Recurrence

Condition: Melanoma
Sponsor: Nina Bhardwaj
Collaborators: New York Univ School of Medicine, MEmorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research, Melanoma Research Alliance, Oncovir, Inc.